Alterations in Ventricular Function: Diastolic Heart Failure: Diastolic Heart Failure

Heart Failure: A Companion to Braunwald's Heart Disease Expert Consult

Volumn , Issue , 2010, Pages 213-231

  Zile, Michael R ^a   Baicu, Catalin F ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85133987167     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5895-3.10014-2     Document Type: Chapter

References (119)

1. Ramachandran S.V., Larson M.G., Benjamin E.J., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999, 33:1948-1955.
2. Lenzen M.J., Scholte op Reimer W.J.M., Boersma E., et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart failure survey. Eur Heart J 2004, 25:1214-1220.
3. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function. Epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004, 43:317-327.
4. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a popular-based study. N Engl J Med 2006, 355:260-269.
5. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
6. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation 2009, 119:e391-e479.
7. Lee D.S., Gona P., Vasan R.S., et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction. Insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009, 119:3070-3077.
8. Yusef S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003, 362:777-781.
9. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure. The ancillary digitalis investigation group trial. Circulation 2006, 114:397-403.
10. Cleland J.G.F., Tendera M., Adamus J., et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
11. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
12. van Veldhuisen D.J., Cohen-Solal A., Böhm M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure). J Am Coll Cardiol 2009, 3(23):2150-2158.
13. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971, 285:1441-1446.
14. Brutsaert D.L., Sys S.U. Diastolic dysfunction in heart failure. J Card Fail 1997, 3(3):225-242.
15. Paulus W.J., Tschöpe C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 20:2539-2550.
16. Yturralde R.F., Gaasch W.H. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005, 47(5):314-319.
17. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide (BNP) in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2001, (in press).
18. Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998, 135:825-832.
19. Yamamoto K., Burnett J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996, 28:988-994.
20. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recording. Circulation 2002, 105:595-601.
21. TschÖpe C., Kašner M., Westermann D., et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005, 26:2277-2284.
22. Grewal J., McKelvie R.S., Persson H., et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008, 102(6):733-737.
23. Apstein C.S., Morgan J.P. Cellular mechanisms underlying left ventricular diastolic dysfunction. Left ventricular diastolic dysfunction and heart failure 1994, Lea & Febiger, Philadelphia. W.H. Gaasch, M.M. LeWinter (Eds.).
24. Ingwall J.S. Energetics of the normal and failing human heart: focus on the creatine kinase reaction. Adv Org Biol 1998, 4:117-141.
25. Solaro, R. J., Wolska, B. M., & Westfall, M. Regulatory proteins and diastolic relaxation. In B. H. Lorell & W. Grossman (Eds.), (1987). Diastolic relaxation of the heart. Boston: Kluwer Academic.
26. Alpert N.R., LeWinter M., Mulieri L.A., et al. Chemomechanical energy transduction in the failing heart. Heart Fail Rev 1999, 4(3):281-295.
27. Tian R., Nascimben L., Ingwall J.S., et al. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 1997, 96:1313-1319.
28. Weiss J.L., Fredericksen J.W., Weisfeldt M.L. Hemodynamic determinants of the time course of fall in canine left ventricular pressure. J Clin Invest 1976, 58:83-95.
29. Smith V.E., Zile M.R., et al. Relaxation and diastolic properties of the heart. The heart and cardiovascular system 1992, Raven Press, New York. H.A. Fozzard (Ed.).
30. Mirsky I., Pasipoularides A. Clinical assessment of diastolic function. Prog Cardiovasc Dis 1990, 32:291-318.
31. Zile M.R., Nishimura R.A., Gaasch W.H. Hemodynamic loads and left ventricular diastolic function: factors affecting the indices of isovolumetric and auxotonic relaxation. LV diastolic dysfunction and heart failure 1994, Lea & Febiger, Philadelphia. W.H. Gaasch, N.M. LeWinter (Eds.).
32. Solomon S.D., Janardhanan R., Verma A., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007, 369(9579):2079-2087.
33. Zile M.R., Gaasch W.H. Load-dependent left ventricular relaxation in conscious dogs. Am J Physiol 1991, 261:H669-H699.
34. Little W.C. Diastolic dysfunction beyond distensibility: adverse effects of ventricular dilatation. Circulation 2005, 112(19):2888-2890.
35. Gaasch W.H., Schick E.C., Zile M.R. Management of left ventricular diastolic dysfunction. Cardiovascular therapeutics. A companion to Braunwald's heart disease 1996, WB Saunders, Philadelphia. T.W. Smith (Ed.).
36. Zile M.R. Hemodynamic determinants of echocardiography derived indices of left ventricular filling. Echocardiography 1992, 9:289-300.
37. Aurigemma G.P., Zile M.R., Gaasch W.H. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006, 113(2):296-304.
38. Zile M.R., Bourge R.C., Bennett T.D., et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J Card Fail 2008, 14(10):816-823.
39. Zile M.R., Bennett T.D., St John Sutton M., et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008, 118(14):1433-1441.
40. Zile M.R., Lewinter M.M. Left ventricular end-diastolic volume is normal in patients with heart failure and a normal ejection fraction: a renewed consensus in diastolic heart failure. J Am Coll Cardiol 2007, 49(9):982-985.
41. Quiñones M.A., Zile M.R., Massie B.M., et al. Chronic heart failure: a report from the Dartmouth diastole discourses. Congest Heart Fail 2006, 12(3):162-165.
42. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113(17):2089-2096.
43. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350(19):1953-1959.
44. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115:1982-1990.
45. Melenovsky V., Borlaug B., Rosen B., et al. Cardiovascular features of heart failure with preserved ejection fraction versus non-failing hypertensive left ventricular hypertrophy in the urban Baltimore community. J Am Coll Cardiol 2007, 49:198-207.
46. Westermann D., Kasner M., Steendijk P., et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008, 117:2051-2060.
47. Borbely A., van der Velden J., Papp Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 2005, 111(6):774-781.
48. van Heerebeek L., Borbély A., Niessen H.W.M., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966.
49. Borbély A., Papp Z., Edes I., et al. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 2009, 61(1):139-145.
50. Borbély A., Falcao-Pires I., van Heerebeek L., et al. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009, 104(6):780-786.
51. Borbély A., van Heerebeek L., Paulus W.J. Transcriptional and posttranslational modifications of titin: implications for diastole. Circ Res 2009, 104(1):12-14.
52. Zile M.R., Conrad C.H., Gaasch W.H., et al. Preload does not affect relaxation rate in normal, hypoxic or hypertrophic myocardium. Am J Physiol 1990, 258:H191-H197.
53. Zile M.R., Gaasch W.H., Weigner A.W., et al. Mechanical determinants of the rate of isotonic lengthening in rat left ventricular myocardium. Circ Res 1987, 60:815-823.
54. Tsutsui H., Urabe Y., Mann D., et al. Effects of chronic mitral regurgitation on diastolic function in isolated cardiocytes. Circ Res 1993, 72:1110-1123.
55. Zile M.R., Mukherjee R., Clayton C., et al. Effects of chronic supraventricular pacing tachycardia on relaxation rate in isolated cardiac muscle cells. Am J Physiol 1995, 268:H2104-H2113.
56. Zile M., Spinale F.G. Diastolic dysfunction and tachycardia-induced heart failure: International Symposium on the Physiology of Diastole in Health and Disease. Diastolic relaxation of the heart 1994, Kluwer Academic Press, Boston. W. Grossman, B. Lorell (Eds.).
57. Zile M.R., Cowles M.K., Buckley J.M., et al. Gel stretch method: a new method to measure constitutive properties of cardiac muscle cells. Am J Physiol 1998, 274:H2188-H2202.
58. Zile M.R., Richardson K., Cowles M.K., et al. Constitutive properties of adult mammalian cardiac muscle cells. Circulation 1998, 98:567-579.
59. Harris T.S., Baicu C.F., Conrad C.H., et al. Constitutive properties of hypertrophied myocardium: cellular contributions to changes in myocardial stiffness and viscosity. Circulation 1998, 98(Suppl. I). I-649.
60. Baicu C.F., Zile M.R., Aurigemma G.P., et al. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005, 111:2306-2312.
61. Carabello B.A. Evolution of the study of left ventricular function: everything old is new again. Circulation 2002, 105:2701-2703.
62. Petri M.C., Caruana L., Berry C., et al. "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction. Heart 2002, 87:29-31.
63. Petrie M., McMurray J. Changes in notions about heart failure. Lancet 2001, 358:432-434.
64. Yip G., Wang Zhang, Y., et al. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition. Heart 2002, 87:121-125.
65. Nikitin N.P., Witte K.K.A. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol 2002, 90:1174-1177.
66. Banerjee P., Banerjee T., Khand A., et al. Diastolic heart failure: neglected or misdiagnosed?. J Am Coll Cardiol 2002, 39:138-141.
67. Yu C., Lin H., Yang H., et al. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002, 105:1195-1201.
68. Steendijk P. Heart failure with preserved ejection fraction: diastolic dysfunction, subtle systolic dysfunction, systolic-ventricular and arterial stiffening, or misdiagnosis?. Cardiovasc Res 2004, 64:9-11.
69. Norton G.R., Woodiwiss A.J., Gaasch W.H., et al. Heart failure in pressure overload hypertrophy: the relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002, 39:664-671.
70. Anand I.S., Daosheng L., Chugh S.S., et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 1997, 96:3974-3984.
71. Anand I.S. Ventricular remodeling without cellular contractile dysfunction. J Card Failure 2002, 8:S401-S408.
72. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure, part I: diagnosis, prognosis, measurements of diastolic function. Circulation 2002, 105:1387-1393.
73. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure, part II: causal mechanisms and treatment. Circulation 2002, 105:1503-1508.
74. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
75. Spinale F.G., Tomita M., Zellner J.L., et al. Collagen remodeling and changes in left ventricular function during development and recovery from supraventricular tachycardia. Am J Physiol 1991, 261(pt 2):H308-H318.
76. Spinale F.G., Zellner J.L., Tomita M., et al. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res 1991, 69:1058-1067.
77. Hein S., Arnon E., Kostin S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart. Circulation 2003, 107:984-991.
78. Gaasch W.H., Delorey D.E., St John Sutton M.G., et al. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. Am J Cardiol 2008, 102(4):459-462.
79. Kostin S., Hein S., Arnon E., et al. The cytoskeleton and related proteins in the human failure heart. Heart Fail Rev 2000, 5:271-280.
80. Cooper G. IV: Cardiocyte cytoskeleton in hypertrophied myocardium. Heart Fail Rev 2000, 5:187-201.
81. Bell S.P., Nyland L., Tischler M.D., et al. Alterations in the determinants of diastolic suction during pacing tachycardia. Circ Res 2000, 87(3):235-240.
82. Cazolla O., Freiburg A., Helmes M., et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000, 86(1):59-67.
83. Tagawa H., Wang N., Narishige T., et al. Cytoskeletal mechanics in pressure overload cardiac hypertrophy. Circ Res 1997, 80:281-289.
84. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
85. Weber K.T., Sun Y., Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994, 23:869-877.
86. Borg T.K., Caulfield J.B. The collagen matrix of the heart. Fed Proc 1981, 40(7):2037-2041.
87. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
88. Covell J.W. Factors influencing diastolic function. Possible role of the extracellular matrix. Circulation 1990, 81(Suppl. III). III-155-III-158.
89. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989, 64:1041-1050.
90. Weber K.T., Janicki J.S., Pick R., et al. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990, 65:1G-7G.
91. Villari B., Campbell S.E., Hess O.M., et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 1993, 22:1477-1484.
92. Villari B., Vassalli G., Monrad E.S., et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995, 91(9):2353-2358.
93. Kato S., Spinale F.G., Tanaka R., et al. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995, 269. H863-H868.
94. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000, 102:1388-1393.
95. Spinale F.S., Coker M.L., Bond B.R., et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000, 46:225-238.
96. Nagatomo Y., Carabello B.A., Coker M.L., et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000, 278:H151-H161.
97. Spinale F.G., Coker M.L., Krombach S.R., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ Res 1999, 85:364-376.
98. Bradshaw A.D., Baicu C.F., Rentz T.J., et al. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in postsynthetic procollagen processing. Circulation 2009, 119(2):269-280.
99. McCurdy S., Baicu C.F., Heymans S., et al. Cardiac extracellular matrix remodeling: fibrillar collagens and secreted protein acidic and rich in cysteine (SPARC). J Mol Cell Cardiol 2010, 48(3):544-549.
100. Davidson J.M., Berg R.A. Posttranslational events in collagen biosynthesis. Methods Cell Biol 1981, 23:119-136.
101. Kielty C.M., Hopkinson I., Grant M.E. Collagen: structure, assembly, and organization in the ECM. Connective tissue and its heritable disorders 1993, Wiley-Liss, New York. P.M. Royce, B.S. Steinmann (Eds.).
102. Nimni M.E. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. Extracellular matrix 1993, Marcel Dekker, New York. M.A. Zern, L.M. Reid (Eds.).
103. Singh R., Barden A., Mori T., et al. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
104. Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995, 18:275-281.
105. Cerami, A., Ulrich, P. Pharmaceutical intervention of advanced glycation endproducts. Ageing vulnerability: causes and intervention. Novartis Found Symp 201;235:202-216.
106. Spinale F. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87(4):1285-1342.
107. Stern D.M., Yan S.D., Yan S.F., et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002, 1:1-15.
108. Yan S.D., Zhu H., Zhu A., et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000, 6:643-651.
109. Kislinger T., Fu C., Huber B., et al. N(epsilon)-carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999, 274:31740-31749.
110. Sun M., Yokoyama M., Ishiwata T., et al. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Pathol 1998, 79:207-222.
111. Schmidt A.M., Yan S.D., Stern D. The biology of RAGE and its ligands. Biochim Biophys Acta 2000, 1498:99-111.
112. Huang J.S., Guh J.Y., Chen H.C., et al. Role of receptor for advanced glycation end-products and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001, 81:102-113.
113. Yan S.F., Ramasamy R., Naka Y., et al. Glycation, inflammation, and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
114. Haber H.L., Powers E.R., Gimple L.W., et al. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation 1994, 89:2616-2625.
115. Friedrich S.P., Lorell B.H., Rousseau M.F., et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994, 90:2761-2771.
116. Paulus W.J., Shah A.M. NO and cardiac diastolic function. Cardiovasc Res 1999, 43:595-606.
117. Yamamoto K., Burnett J.C., Redfield M.M. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997, 273:H2406-H2414.
118. Clarkson P.B., Wheeldon N.M., et al. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation 1996, 93:2037-2042.
119. Paulus W.J. Beneficial effects of nitric oxide on cardiac diastolic function: "the flip side of the coin.". Heart Fail Rev 2000, 5(4):337-344.